Expanding beyond IL-2: Developing a TNFR2 Agonist to Selectively Expand Stable Tregs

Time: 9:30 am
day: Day One


  • Explaining how TNRF2 agonist antibodies selectively targets the most immunosuppressive Tregs for expansion autoimmunity and inflammation
  • Understanding antibody structural design to optimize agonism in vivo – it is all about hexamers
  • Planning for large scale clinical trials to provide efficacy in patients